Ralpancizumab

Ralpancizumab (INN;[1] development code RN317) is a monoclonal antibody designed for the treatment of dyslipidemia.[2]

Ralpancizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetneural apoptosis-regulated proteinase 1
Clinical data
Other namesRN317
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
FormulaC6422H9922N1730O2012S54
Molar mass145.3 kg/mol g·mol−1

This drug was developed by Pfizer.

References
  1. World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Ralpancizumab, American Medical Association.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.